One of the challenges we face as a complex organization is that we have so many resources available for so many constituencies, it can be difficult keeping track of everything, and getting the right resources into the right hands.

To that end, here’s a cheat sheet for one key constituency – the leaders of our committees. The items below are certainly among the most valuable resources for a SWOG committee chair. A few are specific to research committees, but most are of interest to leaders of our research support and administrative committees and subcommittees as well. And to other Front Line readers!

To access some of the resources below that are on, you’ll first have to log in as a SWOG member. You can do this using your CTEP-IAM credentials or your SWOG Roster ID and password. If you’ve forgotten your password or have other difficulties authenticating, visit the login help page for guidance.

Yes, this is technically more than 10, but “top 23 resources” doesn’t have the same ring. Now ask yourself: should I bookmark this post?


Trial of the Week

S2107: Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

S2107 continues SWOG’s work from S1406 developing better treatments for BRAF-mutated colorectal cancer (which accounts for about 10 percent of colorectal cancers). It incorporates an immune checkpoint inhibitor into standard treatment with encorafenib plus cetuximab in a group of patients with a particularly poor prognosis. 

This trial is enrolling patients with metastatic or unresectable adenocarcinoma of the colon or rectum with BRAFV600E mutations who have proficient mismatch repair or microsatellite-stable status and who have had one or two prior lines of treatment. The primary endpoint is progression-free survival.

Since its activation in June of 2022, the study has enrolled 37 of its target of 84 patients. The trial is now open at about 240 institutions, with MD Anderson Cancer Center and Ochsner Medical Center Jefferson in New Orleans as the accrual leaders.

Van Karlyle Morris, MD, of the MD Anderson Cancer Center is study chair. 

Learn more on the SWOG S2107 page or the CTSU S2107 page. An S2107 trial summary, CIRB-approved for use with your patients, is also available.